ResMed Inc. (NYSE:RMD) acquired Ectosense N.V. on October 1, 2021. ResMed will continue to sell its ResMed ApneaLink Air home sleep test device. Ectosense will operate within ResMed’s Sleep and Respiratory Care business. The transaction is not material to ResMed’s consolidated financial results. ResMed Inc. (NYSE:RMD) completed the acquisition of Ectosense N.V. on October 1, 2021.